KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Debt (2017 - 2025)

Aquestive Therapeutics has reported Total Debt over the past 9 years, most recently at $37.5 million for Q4 2025.

  • Quarterly results put Total Debt at $37.5 million for Q4 2025, up 15.33% from a year ago — trailing twelve months through Dec 2025 was $37.5 million (up 15.33% YoY), and the annual figure for FY2025 was $37.5 million, up 15.33%.
  • Total Debt for Q4 2025 was $37.5 million at Aquestive Therapeutics, up from $36.3 million in the prior quarter.
  • Over the last five years, Total Debt for AQST hit a ceiling of $54.2 million in Q1 2022 and a floor of $16.1 million in Q1 2024.
  • Median Total Debt over the past 5 years was $38.6 million (2021), compared with a mean of $39.2 million.
  • Biggest five-year swings in Total Debt: tumbled 61.92% in 2024 and later surged 109.22% in 2025.
  • Aquestive Therapeutics' Total Debt stood at $53.6 million in 2021, then dropped by 2.67% to $52.1 million in 2022, then plummeted by 47.21% to $27.5 million in 2023, then grew by 18.15% to $32.5 million in 2024, then rose by 15.33% to $37.5 million in 2025.
  • The last three reported values for Total Debt were $37.5 million (Q4 2025), $36.3 million (Q3 2025), and $35.0 million (Q2 2025) per Business Quant data.